GNLX
Genelux Corporation- Healthcare
- Biotechnology
- $91M market cap
Forecast run · Oct 29, 2026Upside rank 710 of 3,186
Model Signal
ForecastQ Daily Probabilities
40.0%
68.7%
35.5%
Analyst Consensus
Recommendation2.33/5 Buy
Last price$2.00
Price target$17.33
Implied move+766.5%
Analysts3
ForecastQ Portfolios
GNLX is not in any ForecastQ portfolio today. The model scores it with every run; the names it picked are in Portfolios.
Company Profile
Genelux Corporation is a clinical-stage biopharmaceutical company focused on pioneering advanced oncolytic viral immunotherapies for patients confronting aggressive and/or hard-to-treat solid tumor malignancies. Its leading experimental drug, Olvi-Vec, is a proprietary, engineered vaccinia virus strain being developed to address ovarian cancer and non-small cell lung cancer. The company is also advancing V2ACT Immunotherapy for pancreatic cancer, alongside V-VET1 for the treatment of both hematologic and solid cancers. Founded in 2001, Genelux maintains its headquarters in Westlake Village, California.